Understanding how tamoxifen affects endometrial cancer risk
Mechanisms of tamoxifen-associated endometrial cancer risk
['FUNDING_R21'] · UNIVERSITY OF UTAH · NIH-10815809
This study is looking into how tamoxifen, a common breast cancer treatment, might raise the chances of getting endometrial cancer, so we can better understand this risk and help breast cancer patients stay healthier.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-10815809 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which tamoxifen, a common treatment for breast cancer, may increase the risk of endometrial cancer. The study aims to uncover how tamoxifen interacts with estrogen receptors in different tissues, particularly focusing on the endometrium. By using advanced techniques to analyze the molecular interactions involved, researchers hope to clarify the factors that contribute to this risk. This knowledge could lead to improved treatment strategies for breast cancer patients who are at risk of developing endometrial cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients who are prescribed tamoxifen and are concerned about the associated risks.
Not a fit: Patients who are not receiving tamoxifen or those without a history of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for breast cancer patients taking tamoxifen, reducing their risk of endometrial cancer.
How similar studies have performed: While there have been studies on tamoxifen's effects, this research aims to explore novel molecular mechanisms that have not been fully understood, making it a potentially groundbreaking investigation.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GERTZ, JASON — UNIVERSITY OF UTAH
- Study coordinator: GERTZ, JASON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, Breast Cancer